Does Adding Sitagliptin to Metformin Improve Pancreatic Function Through Anti-Inflammatory Effects?

Summary:

In patients with type 2 diabetes inadequately controlled on metformin (n=60), adding sitagliptin 100 mg/day to metformin 2000 mg/day for 12 weeks significantly improved fasting glucose, cholesterol, TyG index, and pancreatic β-cell function while reducing IL-1, IL-6, and IL-18 levels compared to metformin alone, with no significant changes in HbA1c or vitamin D3.

Clinical Context

Metformin remains the first-line pharmacotherapy for type 2 diabetes, but many patients require treatment intensification to achieve glycemic targets. DPP-4 inhibitors like sitagliptin are commonly added to metformin due to their complementary mechanisms, good tolerability, and weight neutrality. While the glycemic efficacy of this combination is well-established, the underlying mechanisms—particularly effects on pancreatic function and inflammation—warrant further investigation.

Chronic low-grade inflammation plays a central role in type 2 diabetes pathophysiology, contributing to insulin resistance, β-cell dysfunction, and cardiovascular complications. Inflammatory cytokines including IL-1β, IL-6, and IL-18 are elevated in diabetes and have been implicated in disease progression. Identifying anti-inflammatory effects of diabetes therapies may explain benefits beyond glucose lowering.

This trial specifically evaluated whether sitagliptin addition to metformin improves pancreatic β-cell function and whether such improvements correlate with changes in inflammatory cytokine levels, providing mechanistic insight into the metformin-DPP-4 inhibitor combination.

Clinical Pearls

1. Improved Pancreatic Function: The significant improvement in HOMA-B (β-cell function index) with sitagliptin addition suggests preserved or enhanced insulin secretory capacity. This is clinically meaningful as β-cell preservation may slow diabetes progression and delay insulin requirement.

2. Anti-Inflammatory Effects: Reductions in IL-1, IL-6, and IL-18 provide evidence for anti-inflammatory mechanisms of sitagliptin. IL-1β in particular has been directly implicated in β-cell damage, and IL-1 receptor antagonists have shown benefit in diabetes trials. Sitagliptin’s IL-1 reduction (p=0.034 vs metformin alone) may contribute to pancreatic protection.

3. Metabolic Profile Improvements: Beyond glucose, improvements in cholesterol and TyG index (triglyceride-glucose index, a marker of insulin resistance) suggest broader metabolic benefits. The TyG index reduction indicates improved insulin sensitivity complementing enhanced β-cell function.

4. HbA1c Unchanged Despite Glucose Improvements: The lack of significant HbA1c change despite improved fasting and random glucose may reflect the 12-week duration (HbA1c reflects 2-3 month average) or baseline HbA1c levels. The glucose improvements suggest HbA1c benefit would likely emerge with longer treatment.

Practical Application

For patients with type 2 diabetes inadequately controlled on metformin, adding sitagliptin provides glucose-lowering along with potential benefits for pancreatic function and inflammation. These mechanistic advantages may be particularly relevant for patients earlier in disease course where β-cell preservation is achievable.

The anti-inflammatory effects suggest cardiovascular benefits beyond glycemic control. While DPP-4 inhibitor cardiovascular outcomes trials have shown safety rather than superiority, the inflammatory pathway modulation may contribute to long-term risk reduction not captured in trial durations.

Consider sitagliptin-metformin combination for patients with elevated inflammatory markers or those seeking to preserve pancreatic function. The weight-neutral profile makes it suitable for patients where weight gain is undesirable.

Broader Evidence Context

This study adds mechanistic depth to the established efficacy of DPP-4 inhibitor-metformin combinations. Previous studies have demonstrated glycemic benefits, and this work extends understanding to inflammatory and pancreatic function effects. The findings align with preclinical evidence of GLP-1 and DPP-4 inhibitor effects on β-cell survival and function.

IL-18 is increasingly recognized as a mediator of metabolic inflammation, and its reduction with sitagliptin adds to evidence of inflammasome pathway modulation by incretin-based therapies.

Study Limitations

Moderate sample size (n=60) and 12-week duration limit long-term conclusions. HbA1c not significantly changed may reflect study duration. Single-center Iranian population may not generalize globally. Vitamin D analysis rationale and relevance unclear. Direct measures of β-cell function (e.g., insulin secretion tests) not performed. Inflammatory cytokine measurements at limited timepoints.

Bottom Line

Adding sitagliptin to metformin improves glycemic control, lipid profile, insulin sensitivity, and pancreatic β-cell function while reducing inflammatory cytokines IL-1, IL-6, and IL-18, suggesting anti-inflammatory mechanisms contribute to the metabolic benefits of this combination.

Source: Yaribeygi H, et al. “Addition of sitagliptin to ongoing metformin improved metabolic profile and pancreatic function via normalizing inflammatory cytokines’ levels in patients with type 2 diabetes, a randomized double-blinded clinical trial.” Expert Rev Endocrinol Metab. 2025;20(6):623-631. Read article